MedPath

Detection of Heterogeneity in Central Lung Cancer - EBUS-TBNA and ctDNA Analysis vs. Endobronchial Forceps Biopsy

Not Applicable
Completed
Conditions
Lung Neoplasms
Interventions
Procedure: EBUS-TBNA
Procedure: Endobronchial forceps biopsy
Registration Number
NCT03017183
Lead Sponsor
Wissenschaftliches Institut Bethanien e.V
Brief Summary

Study participants will be selected from clinical routine patients with endobronchial infiltration of a central lung cancer and indication for bronchoscopic sampling.

Consented patients will undergo bronchoscopy for tumor sampling applying two routine sampling methods during one single procedure (EBUS-TBNA and conventional forceps sampling). The sequence of both sampling methods will be randomized in advance.

The resulting tissue samples will be analyzed by a pathologist using multiplex PCR and FISH. The corresponding analysis results will be compared between sampling methods.

Assignment of a subject to a particular therapeutic strategy is not influenced by this protocol. Medicinal products will be used according to current practice and marketing authorisation.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
EBUS-TBNA - Endobrochial Forceps BiopsyEBUS-TBNAIn this arm, EBUS-TBNA will be done first, followed by endobronchial forceps biopsy
Forceps - EBUS-TBNAEBUS-TBNAIn this arm, endobronchial forceps biopsy will be done first, followed by EBUS-TBNA
Forceps - EBUS-TBNAEndobronchial forceps biopsyIn this arm, endobronchial forceps biopsy will be done first, followed by EBUS-TBNA
EBUS-TBNA - Endobrochial Forceps BiopsyEndobronchial forceps biopsyIn this arm, EBUS-TBNA will be done first, followed by endobronchial forceps biopsy
Primary Outcome Measures
NameTimeMethod
Number of detected mutationswithin 7 days after biopsy

The number of different mutations detected based on each biopsy method as well as ctDNA analysis is determined

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Krankenhaus Bethanien gGmbH

🇩🇪

Solingen, NRW, Germany

© Copyright 2025. All Rights Reserved by MedPath